QuidelOrtho price target raised to $136 from $125 at RBC Capital

RBC Capital analyst Conor McNamara raised the firm’s price target on QuidelOrtho to $136 from $125 and keeps an Outperform rating on the shares. The company’s Q4 results were "strong" and, more importantly, the management laid out very clear phasing of earnings progression in 2023 and beyond while making no change to the timing of the expected Savanna launch and maintaining its long-range targets, the analyst tells investors in a research note.